Article: ALK-AbellA[superscript three], the Makers of GRAZAX(R), Present Successful Phase III Clinical Study Results with Children.(Clinical report)

HORSHOLM, Denmark, March 17 /PRNewswire/ --

- Results Show Highly Significant Effect on Rhinoconjunctivitis (Hay Fever) and Asthma Symptoms in Children from age 5 to 16 Years-old

ALK-AbellA[sup.3] yesterday presented successful Phase III clinical study results with GRAZAX(R) in children at the American Academy of Allergy, Asthma & Immunology (AAAAI 2008) taking place in Philadelphia, Pennsylvania this week.

The main results from the GRAZAX(R) GT-12 study were presented to the scientific community. More than 250 patients participated in the randomized, double blind, placebo controlled trial.

In the grass pollen season (using a threshold ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!